{"name":"Kairos Pharma","slug":"kairos-pharma","ticker":"Private","exchange":"Private","domain":"kairospharma.ai","description":"Kairos Pharma is a private company specializing in AI-driven drug discovery and repurposing. The company focuses on developing innovative treatments for various therapeutic areas, including oncology and neurology. With a strong pipeline of promising candidates, Kairos Pharma is well-positioned to make a significant impact in the pharmaceutical industry. As a private company, Kairos Pharma does not publicly disclose financial information, but its strategic partnerships and collaborations with leading research institutions demonstrate its commitment to advancing medical research.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Naveen Krishnamurthy","sector":"AI Drug Discovery / Drug Repurposing","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":2135000,"netIncome":-5447000,"cash":4491000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Kairos-101 patent cliff ($100M at risk)","drug":"Kairos-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Kairos Pharma Partners with University of California to Advance AI-Driven Drug Discovery","summary":"Kairos Pharma announced a strategic partnership with the University of California to leverage AI-driven drug discovery technologies and accelerate the development of novel therapeutics.","drugName":"","sentiment":"positive"},{"date":"2023-11-01","type":"trial","headline":"Kairos Pharma Initiates Phase 2 Clinical Trial for Lead Oncology Candidate","summary":"Kairos Pharma initiated a Phase 2 clinical trial for its lead oncology candidate, evaluating its efficacy and safety in patients with advanced solid tumors.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQOE5yNTlzRVdGdTZUTmZ1Qk10NWdqa1ROQWRoQUpZYzFKSFVpTTR0YTF6MmxrQzdRbUFldkZUOVhqb29JdmtRdm83UmJDTmx0d2txeEpqNWpXUGdVYnpLVDBtU0MtRkR2cTFjZWpFcEplUGJaUjFGZ1U1M0tJeHdRcmo1eVlKcjRDa0tYd29B?oc=5","date":"2026-03-03","type":"deal","source":"Pharmaceutical Technology","summary":"Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology","headline":"Kairos Pharma signs deal for Celyn Therapeutics’ CL-273","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOWlhFeXJuUWprc284d2pHckFQMExvY3ZRUW5tMXlHUElPWHJMQUZxcmN3a1pvR2Y1clJ4WFc1Tkk3SUM4eEczSDB1eHMxMjdRc083X2pZY0ltSGxxdENSZmNYZ0VwSFZuMGJibFVtQllBR1h2Y01TMmp0cEdxbUlsS0kzekxjRkhZU1hxM2tjeDNuaUxzcGNQZE9n?oc=5","date":"2026-03-02","type":"deal","source":"Mugglehead Magazine","summary":"Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics - Mugglehead Magazine","headline":"Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQZVVfdkFINURyMWQ3bnpIU0tkbFJyWEdtRjdxRXdtZUFRZThlalNBcVkzQUNjSmRsWkJZb0ZsU2stbkhWUXRfZ0pEUGdPV004alBzNVJaamhDRVRqR2JkUGlHWUFwNEgzOVh1Njd2R2RuUUFsYTcyVTNudDJMMEFZRUJmemRVMWFOUURCUHpMN20xc0hVMFB2b0llNmNwck9ZN0NmQ0JONnpBbE40ZDE5Tg?oc=5","date":"2026-03-02","type":"deal","source":"TipRanks","summary":"Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy - TipRanks","headline":"Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeTFDT1RyRUhCVS1RaUtEMTZQUEM5bVVYcUZTdjk4NnVXdFlrMjJGMXJvQUVlZWY3QmFBSnMxMndtMk16dS1wcFVYV1FLMnF4QlB5RENCNGdtR0h3UG9ldXFOV1Q2ajd2Mm5uLWRwV0Mxai1CUU1FdVBtdHRPYmh6WC1aSEhwUmlSYmx4Q2ZYSnhwYVAxR0lEbE9zWDRzUXdaRzI4Nm9kMGJTUmFxRG5CNzJDaw?oc=5","date":"2026-03-02","type":"deal","source":"Stock Titan","summary":"AI-designed lung cancer drug deal puts Kairos in $16.2B market - Stock Titan","headline":"AI-designed lung cancer drug deal puts Kairos in $16.2B market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPbWVnU3MzbHA0Z193Vm9IT3FxZGIwczVoLXNtbUJBVENpZ1ZHZkJ0OXlOdlFpcHlueTNKZF9aemtiM1BCLXpiZXhEeW1nU1dCWVN5dl8wNEVOcGszTU9YSUhqUmZTMGtrbmlsOC02NGpUaXhudWJwNGFFN3loWFhKY2hZS2Nvdmh4bTZidzZfWVdDTVRsT1phSl9xZjJhMUc0WmMyRUVjNnhXZw?oc=5","date":"2026-03-02","type":"deal","source":"Stock Titan","summary":"Kairos Pharma (NYSE American: KAPA) signs deal for CL-273 lung cancer drug - Stock Titan","headline":"Kairos Pharma (NYSE American: KAPA) signs deal for CL-273 lung cancer drug","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPamFSU0JiaEU0TGVucnNtbjJVT3VOMC1GQVlGOWVrMkprU2FqVXJodEw3OWdzajM4ZXZnSnVUWHdFbng1bVFiYWEzUUlidll2TDNBbTdRZThuajhnRjhQcC1wd0V3UXBMZVQ1eFRVUGtuNjlVVnpYTTJ2aGkxcm4zYlZkM3VBRTZ6?oc=5","date":"2026-02-27","type":"trial","source":"Oncology Pipeline","summary":"Kairos expands lung resistance strategy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Kairos expands lung resistance strategy | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1xSi10aC1rZktzNFhyUjNMOHhBUnpMSzUyVXh6Vk1tNTRKMWUtZkp1SkY2dTBYTTF5dF9udXY1R3I0cnJJeG9IYkp1eWJMUVIzWjlYZ2VMOU5GVlphenZTN05Pbmg2a1BCV1ZZd01jVGdDdw?oc=5","date":"2025-09-19","type":"trial","source":"Clinical Trials Arena","summary":"Kairos Pharma reports positive data from Phase II prostate cancer treatment trial - Clinical Trials Arena","headline":"Kairos Pharma reports positive data from Phase II prostate cancer treatment trial","sentiment":"positive"},{"date":"2025-09-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1aM2w4WE1DRy0yaWxFdkROSXdFXzBaNE9WWWZFdnRhMFF2am1FVFhta1RWSmxPY3Nqcy1uTDhCaUVjWTQtWkxTM1lNTHNHXzJuRUFQZHBRZjZmMnJVc0U3VXpqeU1MOFhoek9GZ3JQTkxLUmhSVEE?oc=5","date":"2025-09-11","type":"pipeline","source":"MarketBeat","summary":"Kairos Pharma (KAPA) Short Interest & Short Float | Updated Apr 2026 - MarketBeat","headline":"Kairos Pharma (KAPA) Short Interest & Short Float | Updated Apr 2026","sentiment":"neutral"}],"patents":[{"drugName":"Kairos-101","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Biogen","Pfizer","Roche"],"therapeuticFocus":["Oncology","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2135000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5447000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4491000,"cashHistory":[],"totalAssets":6540000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}